According to GlobalData’s medical device pipeline database, 35 Viscosupplementation devices are in various stages of development globally. GlobalData’s report Viscosupplementation provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 17 are in active development, while the remaining 19 are in an inactive stage of development. There are five products in the early stages of development, and the remaining 12 are in the late stages of development.
Viscosupplementation is the process by which the synovial fluid at the joints is replaced by a Hyaluronate preparation which has viscous properties similar to the natural synovial fluid. Viscosupplementation is used for the treatment of osteoarthritis of knee and other joints. Other joints include hip, shoulder, ankle, elbow, wrist, hand and foot. Viscosupplementation consists of a treatment cycle of Hyaluronic acid injections which come in variable volumes. One cycle is comprised of 1-injection or 3-injection or 5-injection course.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Viscosupplementation pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Viscosupplementation devices. Overall, most of these Viscosupplementation pipeline devices are being developed by private entities.
Key players involved in the active development of Viscosupplementation include Anika Therapeutics, Kalvista Pharmaceuticals, Ampio Pharmaceuticals, Herng Shan, Labrha International, Seikagaku, Shin Poong Pharm, University of Kansas, LG Chem and Lineage Cell Therapeutics.
For a complete picture of the developmental pipeline for Viscosupplementation devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
